Alk-abello A/s Class B · OMXCOP:ALK_B
Alk-abello A/s Class B — Alk-Abello As B Shs New — Q1 2025 Earnings Presentation
12 slides from Alk-abello A/s Class B's earnings presentation, May 6, 2025
Slide 1: Q1 2025 presentation
Q1 2025 presentation Webcast 6 May 2025
Slide 2: Agenda and presenters
2 Webcast 6 May 2025 Agenda and presenters • Q1 highlights • Performance o Market sales trends o Product sales trends o Financials • Strategy highlights President & CEO EVP, Group CFO VP, Head of IR o Paediatric roll-out Peter Halling Claus Steensen Sølje Per Plotnikof o neffy® roll-out • 2025 outlo
Slide 3: Q1 highlights
3 Webcast 6 May 2025 Q1 highlights ALK off to a solid start in 2025 • Results were strong as expected despite some quarterly phasings • Double-digit growth in all sales regions • Tablet sales up 22%, driven by volumes • Progress for children and neffy® agenda • EBIT margin boosted by 2024-optimisati
Slide 4: Double-digit growth in all regions
4 Webcast 6 May 2025 Double-digit growth in all regions Market sales trends Europe North America International markets 72% 16% 12% Volume-driven growth for tablets US sales recovered from stagnancy 41% growth in tablet revenue; and SLIT-drops with growth in all product lines As planned, no SCIT ship
Slide 5: Tablets continue to be the main source of growth
5 Webcast 6 May 2025 Tablets continue to be the main source of growth Product sales trends Tablets SCIT/SLIT-drops Other products 56% 33% 11% Double-digit growth in all regions; Slight decrease in EU SCIT sales; Improved US momentum (life- EU sales up 17% on higher volumes no SCIT shipments to China
Slide 6: Sales growth drives margin improvements
6 Webcast 6 May 2025 Sales growth drives margin improvements Q1 profitability impacted by optimisations and usual revenue seasonality DKK million Q1 2025 Q1 2024 Change Gross profit DKKm Revenue 1,522 1,351 +12% 1.500 70% 65% Gross profit 1,016 889 1.000 60% 500 Gross margin 67% 66% 55% 0 50% Q1-24
Slide 7: Allergy+ progresses across disease areas
7 Webcast 6 May 2025 Allergy+ progresses across disease areas Focus on high-potential growth levers Respiratory allergy Innovate • Approvals of house dust mite and tree tablets for use in children We will innovate 2028 • Expansion of addressable markets to create a balanced pipeline • Bridging trial
Slide 8: Seizing the paediatric opportunity
8 Webcast 6 May 2025 Seizing the paediatric opportunity All respiratory tablets now approved for children in key markets ACARIZAX® / ODACTRA® for children aged 5-11 • Currently available in 12 markets • Initial market response exceeded expectations • Confirmed prescribers include a broad range of me
Slide 9: Expanding in anaphylaxis
9 Webcast 6 May 2025 Expanding in anaphylaxis Launches of EURneffy® expected from Q3 onwards Existing partnership with ARS Pharma • Market access negotiations for 2 mg device on track in EU countries • Ongoing review of 2 mg dose in Canada and the UK • Ongoing review of 1 mg dose (small children) in
Slide 10: 2025 outlook is unchanged
10 Webcast 6 May 2025 2025 outlook is unchanged Manageable impact from trade wars, tariffs and global unrest Revenue Key assumptions • Volume-driven growth across regions and product lines DKKm Revenue Growth in l.c. 9-13% • Double-digit growth in tablet sales 7.000 6.000 20% 5.000 15% Growth in • S
Slide 11: Q&A session
Q&A session
Slide 12: Upcoming events
12 Webcast 6 May 2025 Upcoming events • May 6 Q1 roadshow, Copenhagen • May 19 Roadshow, London • June 3 Carnegie Health Care Day, Paris • June 4-5 Jefferies Global Healthcare Conference, New York • June 26 ABG Nordic Opportunities, Frankfurt • August 21 Q2 Interim report Investor Relations: Per Plo
Alk-Abello As B Shs New — Q1 2025 Earnings Presentation on 6ix